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Abstract
Background: Suicidal thoughts and behaviours during antidepressant treatment, especially during
the first weeks of treatment, have prompted warnings by regulatory bodies. The aim of the present
study is to investigate the course and predictors of emergence and worsening of suicidal ideation
during tricyclic antidepressant and serotonin reuptake inhibitor treatment.
Methods: In a multicentre part-randomised open-label study, 811 adult patients with moderate to
severe unipolar depression were allocated to flexible dosage of escitalopram or nortriptyline for
12 weeks. The suicidality items of three standard measures were integrated in a suicidal ideation
score. Increases in this score were classified as treatment emergent suicidal ideation (TESI) or
treatment worsening suicidal ideation (TWOSI) according to the absence or presence of suicidal
ideation at baseline.
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Results: Suicidal ideation decreased during antidepressant treatment. Rates of TESI and TWOSI
peaked in the fifth week. Severity of depression predicted TESI and TWOSI. In men, nortriptyline
was associated with a 9.8-fold and 2.4-fold increase in TESI and TWOSI compared to escitalopram,
respectively. Retirement and history of suicide attempts predicted TWOSI.
Conclusion: Increases in suicidal ideation were associated with depression severity and decreased
during antidepressant treatment. In men, treatment with escitalopram is associated with lower risk
of suicidal ideation compared to nortriptyline. Clinicians should remain alert to suicidal ideation
beyond the initial weeks of antidepressant treatment.
Trial registration: EudraCT (No.2004-001723-38) and ISRCTN (No. 03693000).
Background
Every year more than 100,000 men and women commit
suicide in Europe [1]. Mental disorders, especially depres-
sion, are present in more than 90% of suicides, and over
80% are untreated at the time of death [2,3]. While it is
known that antidepressant medication alleviates depres-
sion, recent randomised controlled trials (RCTs) in adults
have left the verdict open as to whether antidepressants
reduce suicidal thoughts and behaviours [4,5]. Reports of
higher rates of suicide-related adverse events during treat-
ment with selective serotonin reuptake inhibitors (SSRIs)
and other antidepressants compared to placebo have
prompted regulatory bodies in the US and Europe to issue
warnings alerting clinicians to the risk of suicide during
the first weeks of antidepressant treatment [6,7]. These
warnings have had an impact on prescribing and may
have paradoxically increased the risk of suicide in the pop-
ulation [8].
The incidence of treatment emergent suicidal ideation
(TESI) varies from 4% to 20%, depending on the defini-
tion of suicidal ideation and sample characteristics [9-13].
The risk has been reported to be highest within the first
week of treatment or after an alteration of dose [14]. Sev-
eral risk factors have been proposed, including severity of
depression, younger age at onset, younger adults [11,13]
and genetic factors [9,12]. Male gender has also recently
been associated with worsening of suicidal ideation dur-
ing citalopram treatment [15]. As there are controversies
about gender differences in antidepressant treatment
response, it is warranted to investigate moderation of sui-
cidal ideation during such treatment by gender [16]. Per-
haps the most clinically relevant, but as yet unanswered,
question is whether a specific type of antidepressant (for
example, SSRIs or tricyclic antidepressants (TCAs)) is
associated with higher risk of TESI [4,13,14,17,18]. The
Genome-Based Therapeutic Drugs for Depression (GEN-
DEP) trial, the largest comparative study of an SSRI and
TCA, is well suited to address this question.
Several previous investigations have been restricted to the
emergence of suicidal ideation in individuals who
reported no suicidal ideation at baseline. Whilst this
approach highlights the relatively rare cases with de novo
treatment emergent suicidal ideation, the potential for
worsening of existing suicidal ideation during treatment
with antidepressants remains relatively unexplored, thus
risking 'throwing the baby out with the bath water'
through removing a large proportion of patients at risk.
Several other limitations could be raised concerning the
measure of emergence of suicidal ideation in previous
investigations. Firstly, most of these studies used only one
scale to measure suicidal ideation: a more sensitive self-
report questionnaire, risking false positives [9,12] or a
more specific clinician-rated scale [10,11,13] risking false
negatives. Secondarily, by using only one scale, a lot of
missing values are encountered during the follow-up lead-
ing to loss of data. Thirdly, some of the investigations did
not have repeated measures of suicidal ideation across the
treatment period and only focused on the first weeks of
treatment, potentially missing important information on
the course of suicidal ideation [9,12]. Therefore, we here
report, in a secondary analysis of GENDEP, the course and
predictors of both emergence and worsening of suicidal
ideation over 12 weeks of antidepressant treatment. More-
over, in order to use all available data and provide unbi-
ased estimates in the presence of missing values, we apply
the item response theory (IRT) [19,20] to derive the best
estimate of suicidal ideation from the suicidality items of
three rating scales: one self-report questionnaire and two
clinician-rated scales.
Methods
Sample and study design
The sample comprised 811 subjects with major depressive
disorder taking part in GENDEP, a partially randomised
multicentre clinical and pharmacogenomic study [21].
Participants were included if they met criteria for a major
depressive episode of at least moderate severity, as defined
by the Diagnostic and Statistical Manual, fourth edition
(DSM-IV) and International Classification of Diseases,
10th revision (ICD-10) criteria, established using the
Schedules for Clinical Assessment in Neuropsychiatry
(SCAN, version 2.1) [22]. Patients with no contraindica-BMC Medicine 2009, 7:60 http://www.biomedcentral.com/1741-7015/7/60
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tions were randomly allocated to receive flexible dosage
nortriptyline (50 to 150 mg daily) or escitalopram (10 to
30 mg daily) for 12 weeks. Patients with contraindications
for one of the drugs were allocated non-randomly to the
other antidepressant. Participants who could not tolerate
the initially allocated medication or who did not experi-
ence sufficient improvement despite adequate dosage for
8 weeks were offered a change to the other medication.
Participants who changed medication were then fol-
lowed-up using the same protocol as for the first antide-
pressant. All subjects were of European ethnicity and
between 18 and 72 years of age. The exclusion criteria
were: a first-degree relative with bipolar affective disorder
or schizophrenia, a history of hypomanic or manic epi-
sode, mood incongruent psychotic symptoms, primary
substance misuse or primary organic disease, current treat-
ment with an antipsychotic or a mood stabilizer, and
pregnancy or lactation. A total of 15 subjects who had
missing data on all three suicidality items at baseline were
excluded.
The study protocol was approved by research ethics com-
mittees in each centre. After describing the study to the
subjects, written informed consent was obtained. The
GENDEP trial is registered at EudraCT (no. 2004-001723-
38) and ISRCTN (no. 03693000).
Severity of depressive disorder
Severity of depressive disorder was based on the 'observed
mood' dimension derived by factor analysis of categorical
items form three rating scales and scored through an item
response theory procedure [20]. The 'observed mood'
dimension is a highly internally consistent measure, com-
prising symptoms of depressed mood, activity, anxiety
and psychomotor disturbance rated by the clinician. It
contains information from items that constitute the previ-
ously suggested 'core' subscales of the Hamilton Rating
Scale for Depression (HRSD) [23], and is therefore suita-
ble for testing hypotheses related to pharmacological
modulation of mood. Most importantly, this dimension
does not contain any information from the suicidality
items and thus there is no overlap of content with the sui-
cidal ideation measures. For this reason, observed mood
is suitable as a covariate in models that test suicidal idea-
tion as the outcome of interest.
Suicidal ideation
Suicidal ideation was assessed using a composite score
based on the 3rd item of the 17-item HRSD (HRSD-17),
the 9th item of the self-report 21-item Beck Depression
Inventory (BDI) and the 10th item of the clinician-rated
10-item Montgomery-Asberg Depression Rating Scale
(MADRS). The response options for these items are shown
in Table 1.
As there is imperfect correspondence in the content and
number of response options between these three scales,
and as no scale had been proven to be optimal by itself to
measure depression severity or suicidal ideation [20,24],
we used the item response theory (IRT) graded response
model to derive the best estimate of suicidal ideation from
the suicidal items of the three rating scales. The IRT scor-
ing allows the use of all available data and provides unbi-
ased estimates in the presence of missing values [19,20].
The IRT-derived standardised composite score (θ) of sui-
cidal ideation (ranging from -0.425 to 3.241) correlated
0.97, 0.92 and 0.77 with MADRS, HRSD-17, and BDI sui-
cidal items, respectively. The discrimination (α) and
threshold (β) parameters for the suicidal items are given
in Table 2. The discrimination parameter α indexes an
item's ability to differentiate between levels of suicidal
ideation and the threshold parameters (β) are estimated
points of transitions between subsequent response
Table 1: Range of response options for HDSR-17, MADRS and BDI suicide items
Scale Score Meaning
HRSD-17 0 Absent
1 Feels life is not worth living
2 Wishes he/she were dead, or any thought of possible death to self
3 Suicide ideas or half-hearted attempt
4 Attempts suicide
MADRS 0 to 1 Enjoys life or take it as it comes
2 to 3 Weary of life. Only fleeting suicidal thoughts.
4 to 5 Probably better off dead. Suicidal thoughts are common, and suicide is considered as a possible solution, but without 
specific plans or intentions.
6 Explicit plans for suicide when there is an opportunity. Active preparation of suicide
BDI 0 Absent
1 Thought of killing myself
2 I would like to kill myself
3 I would like to kill myself if I had a chance
BDI = Beck Depression Inventory; HRSD = Hamilton Rating Scale for Depression; MADRS = Montgomery-Asberg Depression Rating Scale.BMC Medicine 2009, 7:60 http://www.biomedcentral.com/1741-7015/7/60
Page 4 of 14
(page number not for citation purposes)
options on a latent continuous dimension of suicidal ide-
ation, in units of 1 standard deviation (SD). Of note, the
threshold of the first non-zero response option was 0.64
on BDI, 0.03 on MADRS, and 0.4 on HRSD-17, indicating
that BDI was not only less discriminative but also less sen-
sitive than the clinician-rated measures (Table 2).
We defined significant suicidal ideation as an IRT score of
at least 1 SD above 0 (0 scores on all three scales corre-
sponded to -0.425 on the standardised IRT θ scale; thus
0.575 or more is considered as significant suicidal idea-
tion). This threshold corresponds to the 75th percentile of
baseline scores and captures individuals reporting signifi-
cant suicidal ideation (score of 1 or more on BDI and
HRSD-17; 2 or more on MADRS) on at least two of the
three scales. This is consistent with previous definitions of
treatment-emergent suicidal ideation using the 'thoughts
of death or suicide' as a threshold (Table 3). Based on this
definition, 473 participants reported significant suicidal
ideation at baseline. Most of them (67%) reported sui-
cidal ideation on all three measures.
TESI was defined as any increase above the threshold (θ =
0.575) at any point during treatment in individuals with-
out suicidal ideation at baseline. To avoid classifying indi-
viduals as TESI when their IRT score increased minimally
due to variation in the proportion of missing data, an
additional criterion of an increase of at least 0.5 SD was
employed.
Treatment worsening suicidal ideation (TWOSI) was
defined as an increase of suicidal ideation of at least 0.5
SD above the individual's baseline score at any point dur-
ing the study in individuals with significant suicidal idea-
tion at baseline.
Statistical analysis
We used a generalised linear latent and mixed model
(GLLAMM) in Stata (Stata, College Station, TX, USA) with
adaptive quadrature to obtain maximum likelihood esti-
mates for the individual random intercept and slope
model and to assess clinical and demographic predictors
of TESI and TWOSI [25]. The strength of the maximum
likelihood estimation is that no information is lost and it
is robust to missing data. To relax the assumption of con-
ditional independence in the responses of the same per-
son and for the same centre of recruitment, we included a
subject-specific random intercept nested in a centre-spe-
cific random intercept. This method provides more accu-
rate measures of confidence intervals than traditional
logistic models, which tend to underestimate uncertainty
if data, as in this instance, have a hierarchical structure.
Subjects who changed medication were included under
both medications with individual-level clustering being
controlled by the random effect of individual. The analy-
ses assumed a binomial error distribution. Potential pre-
dictors were included as fixed factors, change in drug
dosage and depression severity were included as time-var-
ying predictors. Age was firstly analysed as a continuous
variable and secondarily as a categorical variable accord-
ing to US Federal Drug Administration (FDA) recommen-
dations: lower than 25 years old versus 25 years or older
[7]. Interactions between gender, age and drug were also
tested.
Three comparisons were made: (i) any increase in suicidal
ideation (TESI/TWOSI) versus no increase in the whole
sample, (ii) TESI versus no TESI among subjects without
suicidal ideation at baseline, (iii) TWOSI versus no
TWOSI among subjects with suicidal ideation at baseline.
Two sensitivity analyses were conducted to test the robust-
ness of results. First, to check whether results hold for
larger increases in suicidal ideation, we repeated all anal-
yses with a higher threshold of 1 SD increase in suicidal
ideation. Second, to exclude the influence of selection
bias inherent in non-random allocation to drug in a pro-
portion of the sample, we repeated the analyses in a
reduced sample of individuals who were randomly allo-
cated. In the latter set of sensitivity analyses, individuals
who switched from the randomly allocated medication
were considered as missing after the switch.
Mixed linear models as described elsewhere [20] were
used to measure the effect of treatment on the continuous
suicidal score over time. A two-tailed P value < 0.05 was
Table 2: Item response characteristics for the three measures of suicidality
Discrimination parameter (α) Response option thresholds
β1 β2 β3 β4 β5 β6
MADRS suicidality 7.1 0.03 0.8 1.53 1.93 2.57 2.97
HRSD-17 suicidality 6.1 0.4 1.26 1.99 3.11
BDI suicidality 3.1 0.64 1.98 2.66
The threshold parameter β shows the standardised level of severity at which subsequent response options become more likely than the previous 
response option.
BDI = Beck Depression Inventory; HRSD = Hamilton Rating Scale for Depression; MADRS = Montgomery-Asberg Depression Rating Scale.BMC Medicine 2009, 7:60 http://www.biomedcentral.com/1741-7015/7/60
Page 5 of 14
(page number not for citation purposes)
Table 3: Equivalent summed item response theory score estimates for subjects without suicidal ideation at the baseline (NSI) and 
subjects with suicidal ideation at the baseline (SI)
NSI SI
N% θ MADRS HRSD-17 BDI n % θ MADRS HRSD-17 BDI
108 33.4 -0.425 0 0 0 3 0.6 0.613 0 2 1
7 2.2 -0.392 0 0 - 1 0.2 0.626 2 0 -
1 0.3 -0.27 - 0 0 44 9.3 0.655 1 1 1
2 0.6 -0.173 1 0 1 8 1.7 0.707 2 0 1
15 4.6 -0.058 0 0 1 2 0.4 0.742 1 1 2
3 0.9 -0.036 0 0 2 1 0.2 0.746 1 1 3
6 1.9 0.114 0 1 0 2 0.4 0.775 1 2 0
55 17.0 0.163 1 0 0 1 0.2 0.809 2 0 2
6 1.9 0.196 1 0 - 46 9.7 0.845 2 1 0
2 0.6 0.259 1 - 0 2 0.4 0.849 2 - 0
7 2.2 0.288 0 1 1 2 0.4 0.885 - - 1
18 5.6 0.331 1 0 1 7 1.5 0.943 1 2 1
1 0.3 0.353 1 - - 5 1.1 0.962 2 1 -
84 26.0 0.494 1 1 0 79 16.7 0.999 2 1 1
2 0.6 0.539 2 0 0 1 0.2 1.076 2 - 1
6 1.9 0.569 1 1 - 3 0.6 1.14 2 1 2
2 0.4 1.153 2 1 3
9 1.9 1.172 2 2 0
3 0.6 1.206 3 1 0
63 13.3 1.317 2 2 1
5 1.1 1.318 2 2 -
7 1.5 1.356 3 1 1
7 1.5 1.444 2 2 2
4 0.9 1.467 2 2 3
2 0.4 1.483 3 1 2
1 0.2 1.492 4 1 1
4 0.9 1.501 3 2 0
5 1.1 1.548 2 3 1
1 0.2 1.572 2 4 1
50 10.6 1.602 3 2 1
4 0.9 1.627 3 2 -
12 2.5 1.713 3 2 2
2 0.4 1.751 3 2 3
1 0.2 1.774 2 3 3
9 1.9 1.827 3 3 1
17 3.6 1.841 4 2 1
1 0.2 1.893 4 2 -
2 0.4 1.928 3 3 2
81 . 7 1 . 9 5 4 2 2
2 0.4 1.983 3 3 3
10 . 2 2 . 0 1 4 2 3
11 2.3 2.079 4 3 1
1 0.2 2.172 4 3 -
13 2.8 2.199 4 3 2
2 0.4 2.324 4 3 3
1 0.2 2.325 4 4 0
1 0.2 2.387 4 4 1
2 0.4 2.453 5 3 1
1 0.2 2.515 4 4 2
1 0.2 2.553 5 3 2
4 0.9 2.677 5 3 3
1 0.2 2.911 6 3 -
2 0.4 2.954 6 3 3
1 0.2 3.086 6 4 2
1 0.2 3.106 - 4 -
2 0.4 3.241 6 4 3
BDI = Beck Depression Inventory; HRSD = Hamilton Rating Scale for Depression; MADRS = Montgomery-Asberg Depression Rating Scale.BMC Medicine 2009, 7:60 http://www.biomedcentral.com/1741-7015/7/60
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considered as statistically significant. All analyses were
conducted in Stata, version 10.
Power calculation
The overall sample had 97% power to detect a significant
difference between the two drugs at an α level of 0.05
assuming a baseline rate of 10% and an increase of 10%
for the drug associated with higher risk of increase in sui-
cidal ideation. Power to detect interactions was calculated
using Quanto software [26]. We calculated that we had
56% and 78% power to detect an interaction between
drug and gender and between drug and age assuming an
odds ratio (OR) of 2 or more.
Results
Sample baseline characteristics
Figure 1 displays the flow of participants throughout the
study. The baseline demographic and clinical characteris-
tics of the 323 non-suicidal subjects and the 473 suicidal
subjects are shown in Table 4. Subjects who reported sui-
cidal ideation at baseline had more severe depression
(0.75 (0.54) versus 1.06 (0.59), P < 0.0001). More sub-
jects with suicidal ideation at baseline reported a history
of suicide attempts than individuals without suicidal ide-
ation at baseline (19.3% versus 6.3%, P < 0.0001).
Suicidality-related adverse events
Among those reporting significant suicidal ideation at
baseline, two women (44 and 34 years old) randomised
Table 4: Sociodemographic and clinical characteristics of participants without suicidal ideation at the baseline and participants with 
suicidal ideation at the baseline
No suicidal ideation Suicidal ideation
Escitalopram (n = 196) Nortriptyline (n = 127) Escitalopram (n = 254) Nortriptyline (n = 219)
n% n% n% n%
Gender Female 121 62 84 66 156 61 143 65
Marital status Married/
cohabiting
1 0 25 26 7 6 71 2 24 81 1 55 2
Separated/
divorced
43 22 24 19 55 22 45 21
Single 48 25 28 22 67 26 50 23
W i d o w e d 3 28 61 049 4
Children 0 59 30 32 25 77 30 61 28
1 6 3 3 24 6 3 68 3 3 35 8 2 6
2 6 1 3 13 7 2 97 5 2 98 1 3 7
3+ 13 7 12 9 19 7 19 9
Occupation Full-time 
work
72 37 38 30 99 39 75 34
Part-time 
work
21 11 15 12 29 11 28 13
Student 12 6 9 7 18 7 11 5
Homemaker 7 4 7 5 7 3 13 6
R e t i r e d 2 1 1 12 1 1 62 3 9 3 1 1 4
Unemployed 63 32 37 29 78 31 61 28
Number of 
depressive 
episodes
1 7 7 3 92 9 2 38 2 3 27 0 3 2
2 105 53 81 64 138 54 119 54
3 + 1 471 71 3 3 41 4 3 01 4
Number of 
suicide 
attempts
6 3 13 11 37 16 47 23
Mean SD Mean SD Mean SD Mean
Characteristics Age 42.2 11.6 43.8 12.5 43.1 11.8 41.5 11.5
Education 
(years)
12.1 2.9 12.1 3.2 12.1 3.3 12.1 3
Age at onset 33.7 8.7 32 10.3 33 10.6 32.1 9.9
Duration 
(weeks)
19.7 11 17.6 11.5 18.8 12.5 19.3 13.9
Baseline 
severity
Observed 
mood
0.8 0.6 0.7 0.5 1 0.6 1.1 0.6
Suicidal score 0.05 0.4 0.05 0.4 1.3 0.5 1.3 0.5
SD = standard deviation.BMC Medicine 2009, 7:60 http://www.biomedcentral.com/1741-7015/7/60
Page 7 of 14
(page number not for citation purposes)
to escitalopram were admitted to hospital owing to sui-
cidal ideation during the course of the study. Among
those with no significant baseline suicidal ideation, a 55-
year-old woman randomised to nortriptyline committed
suicide in the ninth week of treatment. In the following
analyses, these subjects were considered as having an
increase of more than 1 SD at the time of dropout. Based
on a score of four on the third item of the HRSD-17, and
as shown in Table 3, eight individuals reported a suicide
attempt, all of them at baseline. Only one of them also
reported a suicide attempt during the first week of treat-
ment.
Changes in the continuous suicidal score over the 
treatment period
Treatment with either drug was associated with a signifi-
cant reduction in suicidal ideation over time (β = -0.48; z
= -24.99; P < 0.0001) (Figure 2). Throughout the study,
the mean suicidal score was higher in the nortriptyline-
treated group (β = 0.14; z = 6.55; P < 0.0001). However,
this difference was not significant after adjusting for the
baseline suicidal score (P = 0.449). Age, gender or ran-
domisation status had no effect on change in suicidal ide-
ation over time (P = 0.659, P = 0.801 and P = 0.540,
respectively). Married status was associated with lower
suicidal scores (β = -0.15; z = -3.55; P < 0.0001).
Increases in suicidal ideation score during treatment
In all, 254 subjects (31.9%) had an increase in suicidal
ideation score of at least 0.5 SD at some point during the
study. The highest rate was observed during the fifth week
of treatment (15.5%). Age, gender, and interaction
between these two variables did not predict an increase in
suicidal ideation. In men and women combined, there
was no association of either drug with increases in suicidal
ideation and dose changes had no effect (Table 5). Ran-
dom allocation was associated with increases in suicidal
ideation (Table 5). Randomisation status was therefore
used in all analyses as a covariate. Subjects who switched
medication had a higher rate of increased suicidal idea-
tion (Table 5). There was a gender by drug interaction (P
< 0.0001) with a higher risk of increase in suicidal idea-
tion among men taking nortriptyline compared to men
taking escitalopram (OR = 3.51, 95% confidence interval
(CI) 1.92 to 6.39, P < 0.0001) (Figure 3). Of men taking
nortriptyline, 35.29% (n = 42/119) had an increase in sui-
Flow of participants throughout the study Figure 1
Flow of participants throughout the study.BMC Medicine 2009, 7:60 http://www.biomedcentral.com/1741-7015/7/60
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cidal ideation compared to only 23.70% (n = 41/173) of
those taking escitalopram. This gender by drug interaction
remained significant after adjustment for baseline severity
of depression and severity of depression during the study.
Severity of depression was strongly associated with a
higher rate of increases in suicidal ideation (OR = 4.16,
95% CI 3.24 to 5.35 per standard deviation on observed
mood, P < 0.0001). Younger age at onset and a higher
number of depressive episodes also predicted increases in
suicidal ideation (Table 5). In addition, increases in sui-
cidal ideation were predicted by history of suicide
attempts (OR = 3.59, 95% CI 2.31 to 5.58, P < 0.0001).
Finally, retirement was found to be associated with
increases in suicidal ideation (OR = 9.28, 95% CI 4.61 to
18.72, P < 0.0001).
The results from the two sensitivity analyses were very
similar to the whole sample; all parameter estimates were
in the same direction and well within the 95% confidence
intervals of the parameters derived from the whole sample
analysis.
Emergence of new suicidal ideation during treatment 
(TESI)
Just over 17% (n = 57) of the participants with no baseline
suicidal ideation qualified for the definition of TESI at
some point during follow-up. The highest rate of TESI
(6.6%) was observed during the fifth week of treatment.
TESI was predicted by depression severity during follow-
up (OR = 2.92, 95% CI 1.92 to 4.46 for 1 SD on observed
mood, P < 0.0001), younger age at onset of depression
(OR = 0.16, 95% CI 0.04 to 0.64 for 1 SD increase in age
at onset, P = 0.01), higher number of previous depressive
episodes (more than two previous episodes: OR = 9.7,
95% CI 1.23 to 76.2, P = 0.031), unemployment (OR =
Mean suicidal score unadjusted (a) and adjusted (b) from baseline score for escitalopram and nortriptyline for the 12 weeks of  follow-up Figure 2
Mean suicidal score unadjusted (a) and adjusted (b) from baseline score for escitalopram and nortriptyline for 
the 12 weeks of follow-up. Panels (c) and (d) display the baseline-adjusted mean suicidal score for men and women, respec-
tively, during the 12 weeks of follow-up.BMC Medicine 2009, 7:60 http://www.biomedcentral.com/1741-7015/7/60
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6.84, 95% CI 2 to 23.3, P = 0.002) and being married (OR
= 4.66, 95% CI 1.32 to 16.42, P = 0.017). Drug, age, gen-
der, randomisation status, history of suicide attempts,
education or children did not significantly predict TESI.
There was a significant gender by drug interaction (P <
0.0001), explained by a higher risk of TESI in men taking
nortriptyline compared to men taking escitalopram (OR =
9.83, 95% CI 1.72 to 56.27, P = 0.01). In all, 20.93% (n =
9/43) of men taking nortriptyline had TESI compared to
10.67% (n = 8/75) of those taking escitalopram. This
interaction just missed the threshold for statistical signifi-
cance after adjustment for baseline severity of depression
and severity of depression during the study (P = 0.063).
TESI subjects more often crossed over to a second course
of medication (P = 0.022).
Worsening of pre-existing suicidal ideation during 
treatment (TWOSI)
Of the 473 subjects who reported significant suicidal ide-
ation at baseline, 197 (42%) qualified for TWOSI at some
time during treatment. The highest rate of TWOSI (22%)
was in the sixth week of treatment.
TWOSI was predicted by depression severity during the
follow-up (OR = 3.28, 95% CI 2.49 to 4.32 for 1 SD
increase in observed mood, P < 0.0001), history of suicide
attempts (OR = 2.02, 95% CI 1.15 to 3.45, P = 0.015) and
retirement (OR = 3.25, 95% CI 1.33 to 7.92, P = 0.009).
Drug, changes in dosage, age, gender, age at depression
onset, marital status, education or children did not signif-
icantly predict TWOSI. Randomisation status was signifi-
cantly associated with TWOSI (P = 0.022). There was a
drug by gender interaction (P < 0.0001) due to a higher
risk of TWOSI in men taking nortriptyline than in men
taking escitalopram (OR = 2.47, 95% CI 1.34 to 4.56, P =
0.004). A total of 43.4% (n = 33/76) of men taking
nortriptyline had TWOSI compared to only 33.7% (n =
33/98) of those taking escitalopram. This interaction
remained significant after adjustment for baseline severity
of depression and severity of depression during the study.
Subjects with TWOSI moved significantly more often to
the second course of medication than participants with-
out TWOSI (P < 0.0001).
Table 5: Results of the generalised linear latent and mixed model for TESI, TWOSI and 0.5 standard deviation (SD) increased
TESI TWOSI 0.5 SD
OR P value 95% CI OR Pvalue 95% CI OR Pvalue 95% CI
Age (continuous) 2.04 0.079 0.92 to 4.5 0.91 0.425 0.71 to 1.16 1.33 0.317 0.76 to 2.34
Age (categorical) 6.57 0.149 0.51 to 36.75 0.83 0.629 0.39 to 1.77 1.14 0.452 0.81 to 1.59
Gender 1.76 0.178 0.77 to 3.98 2.33 0.188 0.66 to 8.24 1.91 0.287 0.58 to 6.33
Randomisation status 1.16 0.667 0.58 to 2.32 4.39 0.022 1.23 to 15.64 6.05 0.003 1.82 to 20.07
Drug (nortriptyline vs escitalopram) 1.57 0.431 0.51 to 4.85 1.05 0.797 0.71 to 1.59 1.01 0.947 0.73 to 1.39
Observed mood dimension 2.92 <0.0001 1.92 to 4.46 3.28 <0.0001 2.49 to 4.32 4.16 <0.0001 3.24 to 5.35
Age at onset 0.16 0.01 0.04 to 0.64 0.66 0.296 0.30 to 1.44 0.42 0.037 0.18 to 0.95
Number of episodes (more than 3) 9.7 0.031 1.23 to 76.2 4.17 0.172 0.54 to 32.13 11.05 0.022 1.41 to 86.93
Duration 0.95 0.291 0.86 to 1.04 1 0.325 0.99 to 1.01 1.01 0.065 0.99 to 1.02
Switchers 2.2 0.022 1.11 to 4.35 5.94 <0.0001 4.19 to 8.44 9.47 <0.0001 6.57 to 13.6
Increasing dose 2.03 0.92 0.44 to 9.48 1.31 0.269 0.81 to 2.11 1.42 0.184 0.85 to 2.37
Decreasing dose 1.29 0.84 0.18 to 4.29 0.63 0.567 0.13 to 3 1.05 0.95 0.24 to 4.51
History of suicide attempts 0.85 0.898 0.07 to 9.48 2.02 0.015 1.15 to 3.45 3.59 <0.0001 2.31 to 5.58
Marital status
Married/cohabiting 4.66 0.017 1.32 to 16.42 0.73 0.285 0.41 to 1.29 0.79 0.723 0.23 to 2.81
Separated/divorced 0.24 0.065 0.05 to 1.09 1.24 0.516 0.64 to 2.42 0.81 0.771 0.19 to 3.44
Single 0.38 0.162 0.11 to 1.47 2.02 0.094 0.88 to 4.58 1.85 0.507 0.31 to 11.28
Occupation
Full-time work 0.27 0.073 0.04 to 1.16 0.79 0.402 0.45 to 1.38 0.31 0.062 0.11 to 1.09
Part-time work 1.71 0.725 0.09 to 18.03 1.14 0.754 0.51 to 2.52 1.51 0.631 0.28 to 8.17
Unemployed 6.84 0.002 2 to 23.3 0.75 0.323 0.41 to 1.33 1.82 0.337 0.53 to 6.29
Retired 0.93 0.96 0.08 to 9.58 3.25 0.009 1.33 to 7.92 9.28 <0.0001 4.61 to 18.72
Student* - - - 1.06 0.929 0.32 to 3.46 0.33 0.398 0.02 to 4.34
Children (yes vs no) 1.04 0.978 0.05 to 21.43 0.57 0.124 0.29 to 1.16 0.49 0.378 0.11 to 2.33
Education 1.12 0.504 0.79 to 1.59 0.95 0.264 0.87 to 1.04 0.91 0.358 0.76 to 1.11
Gender by drug interaction <0.0001 <0.0001 <0.0001
Drug among men 
(nortriptyline vs escitalopram)
9.83 0.01 1.72 to 56.27 2.47 0.004 1.34 to 4.56 3.51 <0.0001 1.92 to 6.39
aNo students with TESI were observed.
CI = confidence interval; OR = odds ratio; TESI = treatment emergent suicidal ideation; TWOSI = treatment worsening suicidal ideation.BMC Medicine 2009, 7:60 http://www.biomedcentral.com/1741-7015/7/60
Page 10 of 14
(page number not for citation purposes)
Self-reported suicidal ideation
As the BDI scale correlated the least with our composite
suicidal ideation score (0.77) and this was the only self-
report questionnaire, we repeated all analyses with this
scale alone. The results were very similar to the main find-
ings and all coefficients were in the same direction.
Clinician-rated suicidal ideation
In order to compare our results to an established way of
defining suicidal ideation, we repeated the analyses using
the more stringent traditional cut-off of 2 on the third
item of the HRSD-17. Although this analysis was slightly
less efficient, all results were in the same direction with
estimates within the 95% CIs of our main results and the
gender by drug interaction remained significant (P  =
0.045).
Discussion
We here report time course and predictors of suicidal ide-
ation during treatment with a TCA or an SSRI, evaluating
a comprehensive set of predictors for both treatment-
emergent and treatment-worsening suicidal ideation.
Depression severity during the follow-up was the strong-
est predictor of both TESI and TWOSI. A drug by gender
interaction indicated a higher risk of suicidal ideation dur-
ing treatment with nortriptyline among men irrespective
of the presence of suicidal ideation at baseline. This latter
result was confirmed in a sensitivity analysis restricted to
randomly allocated subjects.
Although it is reasonable to assume that antidepressants
reduce suicidal behaviours by reducing depressive symp-
toms, it has also been suggested that in some cases sui-
cidal thoughts and behaviours might be induced by
antidepressant treatment. Several studies and meta-analy-
ses found an increased risk of suicidal behaviours in
adults treated with SSRIs compared with placebo and/or
TCAs [4,5,18,27-30], but several other reports found no
differences in suicidal behaviours between TCAs and
SSRIs in adults [4,13,14,17,31-33].
In the GENDEP trial, suicidal ideation markedly
decreased during treatment with either nortriptyline or
escitalopram, with no overall difference between the two
Proportion of increases in suicidal ideation by study week among men (a) and women (b) for escitalopram and nortriptyline Figure 3
Proportion of increases in suicidal ideation by study week among men (a) and women (b) for escitalopram and 
nortriptyline.BMC Medicine 2009, 7:60 http://www.biomedcentral.com/1741-7015/7/60
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drugs. However, nortriptyline was associated with a
higher rate of both TESI and TWOSI in men. Few studies
to date have compared the impact of an SSRI and a TCA
on suicidal ideation and none has considered moderation
by gender [32]. The IRT suicidal score provided a sensitive
measure to investigate this issue and to confirm that anti-
depressants are not only effective in reducing depressive
symptoms but also in reducing suicidal ideation. These
findings are in agreement with most epidemiological
studies showing that mortality by suicide declines when
antidepressant use increases [34-36]. The GENDEP results
support a beneficial effect of antidepressants on suicidal
ideation in adults and should encourage clinicians to pre-
scribe antidepressant medication in patients with suicidal
ideation.
One reason why the GENDEP results may differ from
some previous studies is the fact that nortriptyline has a
predominantly noradrenergic action compared to other
TCAs. As overactivity of the noradrenergic system is asso-
ciated with anxiety and agitation, the increase in
noradrenergic transmission induced by nortriptyline may
drive the suicidal risk [37,38]. It has been suggested that
suicidal ideation is more common in agitated and irrita-
ble types of depression [39]. Therefore, it is possible that
nortriptyline may induce or worsen suicidal thoughts in
some male subjects possibly through an induction of this
more agitated type of depression. The drug effect in GEN-
DEP was concentrated in depressed men who suffer from
irritability, anger and aggressive behaviours more often
than women and may therefore be vulnerable to the
enhancement of noradrenergic transmission. Interest-
ingly, the effect of a genetic polymorphism in CREB1 on
anger-related symptoms and on treatment-related suicidal
ideation is also specific to male gender [12].
Another possibility is that the increased risk of suicidal
ideation simply reflects a lower efficacy of nortriptyline
on mood symptoms [21]. We found that participants with
TESI and TWOSI suffered from more severe depression,
had a younger age of onset and a larger number of depres-
sive episodes. This is consistent with several other studies
[9,11,13,40]. Perlis et al. [11] showed that participants
with TESI from the Sequenced Treatment Alternatives to
Relieve Depression (STAR*D) study responded less to
antidepressants and had a more severe form of depres-
sion, and concluded that emergence of suicidal ideation
may be a surrogate marker for lack of improvement. This
concordant finding in the two largest antidepressant-
treated samples to date justifies the interim conclusion
that TESI and TWOSI are associated with an increase, or
lack of improvement, in depressive symptomatology. Our
finding that TESI and TWOSI may also be associated with
emergence of psychomotor activation triggered by
noradrenergic antidepressants leading to suicidal ideation
remains to be evaluated in future studies.
The rates of TESI and TWOSI in GENDEP were higher
than those reported previously [9-13,41]. This could be
due to several reasons. First, the use of three measures to
calculate the suicidal score has increased the sensitivity to
detect suicidal thoughts as compared to studies that only
used one scale. It could be argued that our IRT-derived sui-
cidal ideation estimate encompasses too broad a range of
suicidal ideation. However, the rate of TESI was very sim-
ilar when the traditional threshold of 1 on the BDI was
used to define suicidal ideation [11-13]. Importantly,
results regarding predictors of TESI and TWOSI proved
robust to more stringent thresholds for suicidality in sen-
sitivity analyses. Second, the high rate of suicidal ideation
could reflect the higher severity of depression in the GEN-
DEP sample: the average baseline HRSD-17 score was
21.7 in GENDEP compared to 19.2 in STAR*D. However,
comparisons across studies should be interpreted with
caution, as the methodology and analysis differed signifi-
cantly.
It has been suggested that the highest risk of suicidal
behaviour is in the initial few weeks or even days of treat-
ment with antidepressants [11,13,14,42]. Our findings do
not support this notion and demonstrate that TESI and
TWOSI were relatively evenly distributed over the 12
weeks of follow-up. This is of particular concern, as it
shows that there is little reason for either intensive moni-
toring over the first weeks, or for complacency later in the
course of treatment, which could be an interpretation of
current clinical guidelines [7]. This intriguing result could
be explained by the fact that we did not restrict our analy-
ses to the emergence of suicidal ideation in individuals
who reported no suicidal ideation at baseline but
extended them to the worsening of existing suicidal idea-
tion during treatment with antidepressants. Moreover, in
the GENDEP study each participant was evaluated each
week for 12 weeks giving us the opportunity to examine
the time course of changes in suicidal ideation and thus to
highlight TESI and TWOSI even in the later weeks. In
agreement with our results, Zisook et al. [15] in a recent
analysis of the STAR*D data also found that increase in
suicidal ideation were not confined to the first weeks but
often occur later in the course of the treatment.
We found that prior suicide attempts, unemployment or
retirement were associated with TWOSI and TESI. These
are known predictors of suicidal behaviours [33,43,44].
Surprisingly, married status was associated with a higher
risk of TESI. However, concordant with our findings, a
recent study looking at risk factors for suicide among psy-
chiatric patients found that marriage increased the suicide
risk [44].BMC Medicine 2009, 7:60 http://www.biomedcentral.com/1741-7015/7/60
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Strengths and limitations
GENDEP is the largest clinical trial to date comparing a
TCA with an SSRI and provides sufficient power to detect
events such as emergence or worsening of suicidal idea-
tion. Another advantage of the present study is that the
evaluation of suicidal ideation did not rely on a single rat-
ing scale and was able to integrate self-report with clini-
cian evaluation. This reduces false positives and false
negatives.
As our study is not placebo controlled, we are not able to
distinguish specific effects of SSRIs or TCAs from placebo
effects or natural fluctuations in the course of depression.
The improvement in suicidal ideation could, therefore,
also reflect a natural course with a diminution of symp-
toms in participants with suicidal ideation rather than a
specific effect of drugs. An untreated or placebo-treated
control group would be required to separate specific and
non-specific effects. However, the absence of placebo
allowed inclusion of more severe patients and individuals
who would not have agreed to participate in a placebo-
controlled study, thus increasing the generalisation of our
findings to treatment seeking depressed individuals. Fur-
thermore, the random allocation of a large proportion of
participants to escitalopram or nortriptyline allows an
unbiased comparison of the two antidepressants.
The fact that GENDEP was an open-label study might
have influenced the outcome by modulating patient
expectations. Participants' knowledge of being allocated
to nortriptyline, an 'old antidepressant', could have led to
less positive outcome expectations compared to those
allocated to escitalopram, 'a new antidepressant'. How-
ever, this is unlikely to explain a drug difference that was
found specifically in men, with no effect across the whole
sample. We therefore believe that a biological explanation
of such differential effect is more plausible.
Only one individual reported a suicide attempt while
undergoing treatment in the GENDEP study. This low rate
is in agreement with STAR*D results [9] and precluded
investigating predictors of suicide attempts during antide-
pressant treatment. A synthesis of multiple studies is
needed to explore determinants of actual suicide attempts
during antidepressant treatment.
Another limitation is that our results could not be gener-
alised to other forms of suicidal behaviours such as sui-
cide attempts and suicide completion as the relationship
between these phenomena has been shown to be imper-
fect [45].
Finally, the current study did not take into account the
influence of alcohol or substance use disorders as severe
forms of these constituted exclusion criteria in GENDEP.
Conclusion
Both SSRIs and TCAs were associated with a significant
reduction in suicidal ideation. The present analyses clearly
indicate that TESI and TWOSI are associated with severe
forms of depressive disorder and poor treatment response.
Clinicians should be aware that TCAs are associated with
at least equal risk of treatment-related suicidal ideation as
SSRIs. Retired or unemployed men and those with a his-
tory of past suicide attempts are at particular risk of wors-
ening in suicidal ideation and should be carefully
monitored. The monitoring of suicidal ideation should
not be restricted to the early phases of treatment.
A classification of suicidal ideation during antidepressant
treatment is proposed, taking into account all subjects in
the analyses with either de novo emergence of, or worsen-
ing in, suicidal ideation. The clinical predictors of TWOSI
and TESI were similar, indicating that increase in suicidal
ideation, irrespective of its presence at baseline, is one
phenomenon and should be investigated as such.
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